Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use;Bioequivalencia y genericos. Los estudios de bioequivalencia. I. Una aproximacion a sus bases teoricas, diseno y realizacion

Revista de Neurologia

Volumn 29, Issue 12, 1999, Pages 1235-1246

  Zapater, P ^a   Horga, J F ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Bioequivalence; Carry over effect; Crossover clinical trials; Formulation effect; Generic drugs; Hypothesis of bioequivalence; Limits of bioequivalence; Period effect; Sample size

Indexed keywords

GENERIC DRUG;

BIOEQUIVALENCE; CLINICAL STUDY; DRUG FORMULATION; DRUG RESEARCH; METHODOLOGY; REVIEW; STATISTICAL ANALYSIS; BIOLOGICAL MODEL; CLINICAL TRIAL; CROSSOVER PROCEDURE; HUMAN; PHARMACOKINETICS;

CLINICAL TRIALS; CROSS-OVER STUDIES; DRUGS, GENERIC; HUMANS; MODELS, BIOLOGICAL; THERAPEUTIC EQUIVALENCY;

EID: 0033576360     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.2912.99595     Document Type: Review

References (15)

1. Nierenberg DW, Melmon KL. Introduction to clinical pharmacology. In Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW, eds. Clinical pharmacology. Basic principles in therapeutics. New York: McGraw-Hill; 1992. p. 1-51.
2. Carrasco JL. El método estadístico en medicina. En Carrasco JL, ed. El método estadístico en la investigación médica. Madrid: Ciencia 3; 1983. p. 17-36.
3. Chow S, Liu J. Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker; 1992.
4. Food and Drugs Administration. Division of Bioequivalence. Office of Generic Drugs. Statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Guidance for industry. Rockville: FDA; 1992.
5. European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. December, 1998.
6. Schuirmann DJ. Treatment of bioequivalence data: log transformation. In Proceedings of Bio-International '89-issues in the evaluation of bioavailability data. Toronto, Canada. October 1-4. 1989; 159-61.
7. Pabst G, Jaeger H. Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 1992; 38: 5-10.
8. Mandallaz D, Mau J. Comparison of different methods for decision-making in bioequivalence assessment. Biometrics 1981; 37: 213-22.
9. Rodda BE, Davis RL. Determining the probability of an important difference in bioavailability. Clin Pharmacol Ther 1980; 28: 247-52.
10. Schuirmann DJ. A comparison of the two one-sided tests procedures and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
11. Anderson S, Hauck WW. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. Communications in statistics. Theory and Methods 1983; 12: 2663-92.
12. Steinijans VW, Diletti E. Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 1983; 24: 127-36.
13. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 72-8.
14. Steinijans VW, Hauschke D. Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 105-10.
15. Metzler CM. Sample sizes for bioequivalence studies. Stat Med 1991; 10: 969-70.